DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma

被引:12
作者
Azmi, Asfar S. [1 ]
Li, Yiwei [1 ]
Aboukameel, Amro [1 ]
Muqbil, Irfana [2 ]
Philip, Philip A. [1 ]
Mohammad, Ramzi M. [1 ]
机构
[1] Wayne State Univ, Sch Med, Dept Oncol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA
[2] Univ Detroit Mercy, Dept Chem, Detroit, MI 48221 USA
关键词
XPO1; miR-30; methylation; pancreatic cancer; proliferation; NUCLEAR EXPORT; ANTITUMOR-ACTIVITY; SELECTIVE-INHIBITION; PROMOTER METHYLATION; THERAPEUTIC TARGET; SELINEXOR; CRM1; MICRORNAS; KPT-330; MIRNAS;
D O I
10.3390/cancers11081101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, with high mortality in the United States. One of the important signal transduction proteins involved in the regulation of pancreatic cancer's aggressive progression is the nuclear export protein (XPO1). High expression of XPO1 has been found in pancreatic, lung, breast and other cancers and lymphomas with a poor prognosis of patients with tumors and high proliferative activity of cancer cells. Because XPO1 exports multiple tumor suppressor proteins simultaneously from the nucleus, the inhibition of XPO1 may retain multiple tumor suppressors in the nucleus, resulting in the suppression of cell proliferation and the induction of apoptosis in tumors. In this study, we found that the high expression of XPO1 in pancreatic cancer cells could be, in part, due to the methylation of the miR-30 gene, leading to the low expression level of the miR-30 family. By co-transfection of the XPO1 3'-UTR-Luc target vector with miR-30 mimic, we found that XPO1 is a direct target of the miR-30 family. We also observed that the enforced expression of the miR-30 family inhibited the expression of XPO1, resulting in the suppression of pancreatic cancer growth both in vitro and in vivo. These findings could help to design a novel therapeutic strategy for the treatment of pancreatic cancer by introducing miR-30 into cancer cells.
引用
收藏
页数:15
相关论文
共 49 条
[1]   Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [J].
Alexander, Thomas B. ;
Lacayo, Norman J. ;
Choi, John K. ;
Ribeiro, Raul C. ;
Pui, Ching-Hon ;
Rubnitz, Jeffrey E. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) :4094-+
[2]   Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer [J].
Arango, Natalia Paez ;
Yuca, Erkan ;
Zhao, Ming ;
Evans, Kurt W. ;
Scott, Stephen ;
Kim, Charissa ;
Gonzalez-Angulo, Ana Maria ;
Janku, Filip ;
Ueno, Naoto T. ;
Tripathy, Debu ;
Akcakanat, Argun ;
Naing, Aung ;
Meric-Bernstam, Funda .
BREAST CANCER RESEARCH, 2017, 19
[3]   Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition [J].
Azmi, Asfar S. ;
Muqbil, Irfana ;
Wu, Jack ;
Aboukameel, Amro ;
Senapedis, William ;
Baloglu, Erkan ;
Bollig-Fischer, Aliccia ;
Dyson, Gregory ;
Kauffman, Michael ;
Landesman, Yosef ;
Shacham, Sharon ;
Philip, Philip A. ;
Mohammad, Ramzi M. .
SCIENTIFIC REPORTS, 2015, 5
[4]   Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice [J].
Azmi, Asfar S. ;
Aboukameel, Amro ;
Bao, Bin ;
Sarkar, Fazlul H. ;
Philip, Philip A. ;
Kauffman, Michael ;
Shacham, Sharon ;
Mohammad, Ramzi M. .
GASTROENTEROLOGY, 2013, 144 (02) :447-456
[5]   Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma [J].
Babar, Imran A. ;
Cheng, Christopher J. ;
Booth, Carmen J. ;
Liang, Xianping ;
Weidhaas, Joanne B. ;
Saltzman, W. Mark ;
Slack, Frank J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (26) :E1695-E1704
[6]   Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation [J].
Bagga, S ;
Bracht, J ;
Hunter, S ;
Massirer, K ;
Holtz, J ;
Eachus, R ;
Pasquinelli, AE .
CELL, 2005, 122 (04) :553-563
[7]   XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma [J].
Birnbaum, David Jeremie ;
Finetti, Pascal ;
Birnbaum, Daniel ;
Mamessier, Emilie ;
Bertucci, Francois .
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)
[8]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[9]   MicroRNAs as oncogenes and tumor suppressors [J].
Chen, CZ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1768-1771
[10]   Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer [J].
Chen, Ying ;
Camacho, Sandra Catalina ;
Silvers, Thomas R. ;
Razak, Albiruni R. A. ;
Gabrail, Nashat Y. ;
Gerecitano, John F. ;
Kalir, Eva ;
Pereira, Elena ;
Evans, Brad R. ;
Ramus, Susan J. ;
Huang, Fei ;
Priedigkeit, Nolan ;
Rodriguez, Estefania ;
Donovan, Michael ;
Khan, Faisal ;
Kalir, Tamara ;
Sebra, Robert ;
Uzilov, Andrew ;
Chen, Rong ;
Sinha, Rileen ;
Halpert, Richard ;
Billaud, Jean-Noel ;
Shacham, Sharon ;
McCauley, Dilara ;
Landesman, Yosef ;
Rashal, Tami ;
Kauffman, Michael ;
Mirza, Mansoor R. ;
Mau-Sorensen, Morten ;
Dottino, Peter ;
Martignetti, John A. .
CLINICAL CANCER RESEARCH, 2017, 23 (06) :1552-1563